Example: Heart Attack

Search clinical trials for: Palivizumab

Total 14 results

NCT04938830

Not yet recruiting

MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

Conditions: RSV Infection
NCT04540627

Completed

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

Conditions: Healthy Adult Participants
NCT03959488

Active, not recruiting

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Conditions: Respiratory Syncytial Virus Infections
NCT00233064

Completed

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

Conditions: Chronic Lung Disease
NCT02968173

Completed

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

Conditions: Respiratory Syncytial Virus (RSV)
NCT02442427

Completed

Palivizumab Therapy for RSV-bronchiolitis

Conditions: Respiratory Syncytial Virus-bronchiolitis
NCT00129766

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Conditions: Respiratory Syncytial Virus Infections
NCT01466062

Completed

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Conditions: Respiratory Syncytial Virus Infection
NCT00113490

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Conditions: Motavizumab Administration for a Second Season for RSV Prophylaxis
NCT00316264

Completed

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Conditions: Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or, Premature With Gestational Age <=35 Weeks and <=6 Months of Age
NCT01107535

Completed

Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection

Conditions: Respiratory Syncytial Virus Infection
NCT00538785

Completed

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Conditions: Congenital Heart Disease
NCT01006629

Completed

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Conditions: Respiratory Syncytial Virus Infection, Premature Birth, Bronchopulmonary Dysplasia, Congenital Heart Disease
NCT00014391

Completed

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Conditions: Cancer